Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Artiva Biotherapeutics, Inc. (ARTV) is a Biotechnology company based in US with a market capitalization of $247.2M. Free cash flow was negative at -$79.3M. This page tracks ARTV's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 96 employees · IPO Jul 19, 2024
Valuation
Valuation & price
$9.78as of May 17, 2026· -27.0% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.25
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$247.2M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$79.3M
Free cash flow (USD)
-$97.1M
Net debt
Net cash position
0.3%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2020 → 2025
Free cash flow by year
2020 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
9
Insider buys · 90 days
5
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 8, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider buyJul 23, 2026Filing
Insider Buy $58KRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $58.3K
- Insider buyJul 23, 2026Filing
Insider Buy $2.6MRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $2.6M
- 8-K eventJul 22, 2026Filing
Annual Meeting Announcement
- Insider buyJul 20, 2026Filing
Insider Buy $1.4MRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $1.4M
- Insider buyJul 14, 2026Filing
Insider Buy $194KRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $194K
- Insider buyJun 29, 2026Filing
Insider Buy $292KRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $292.1K
- Insider buyJun 16, 2026Filing
Insider Buy $4.6MRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $4.6M
- Insider buyJun 11, 2026Filing
Insider Buy $7.7MRA CAPITAL MANAGEMENT, L.P. · Director, 10% Owner · $7.7M
- Insider buyMay 28, 2026Filing
Insider Buy $16.5MGC Corp. · 10% Owner · $16.5M
- Insider sellMay 19, 2026Filing
Insider Sell $244KAslan Fred · Director, Chief Executive Officer · $244.3K
Questions
Frequently asked questions
What is Artiva Biotherapeutics, Inc.'s market cap?
Artiva Biotherapeutics, Inc. (ARTV) has a market capitalization of $247.2M.
What is ARTV's P/E ratio?
A meaningful P/E ratio is not available for ARTV — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is ARTV's price-to-book (P/B) ratio?
ARTV trades at 2.25 times book value per share.
Are insiders buying ARTV stock?
Yes — SEC Form 4 filings show 9 open-market insider buys and 5 sells at Artiva Biotherapeutics, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.